Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$30000.0.

  • Ultragenyx Pharmaceutical's Gains from Investment Securities fell 10179.1% to -$30000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 6787.88%. This contributed to the annual value of $3.5 million for FY2024, which is 3088.35% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Gains from Investment Securities of -$30000.0 as of Q3 2025, which was down 10179.1% from -$189000.0 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Gains from Investment Securities' 5-year high stood at $4.0 million during Q1 2023, with a 5-year trough of -$1.2 million in Q3 2022.
  • Its 5-year average for Gains from Investment Securities is $689631.6, with a median of $271000.0 in 2023.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 58646.15% in 2022, then crashed by 53911.44% in 2024.
  • Ultragenyx Pharmaceutical's Gains from Investment Securities (Quarter) stood at $455000.0 in 2021, then tumbled by 50.55% to $225000.0 in 2022, then rose by 20.44% to $271000.0 in 2023, then plummeted by 539.11% to -$1.2 million in 2024, then soared by 97.48% to -$30000.0 in 2025.
  • Its Gains from Investment Securities stands at -$30000.0 for Q3 2025, versus -$189000.0 for Q2 2025 and $3.0 million for Q1 2025.